{"transactions":[{"id":728670,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Series B Warrant (right to buy)","published_at":"2026-06-23T20:56:17.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 24, 2026, Factor Biosciences Inc. (\"Factor\") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. (\"Common Stock\") and warrants to purchase 462,964 shares of Common Stock (the \"Warrants\"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor."}],"balance_after":231482,"derivative":{"exercise_price":2.16,"underlying":"Common Stock","underlying_shares":231482},"source":{"system":"sec-edgar","filing":"0001193125-26-279703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526279703/ownership.xml","form_type":"4"}},{"id":728669,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Series A Warrant (right to buy)","published_at":"2026-06-23T20:56:17.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 24, 2026, Factor Biosciences Inc. (\"Factor\") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. (\"Common Stock\") and warrants to purchase 462,964 shares of Common Stock (the \"Warrants\"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor."}],"balance_after":231482,"derivative":{"exercise_price":2.16,"underlying":"Common Stock","underlying_shares":231482},"source":{"system":"sec-edgar","filing":"0001193125-26-279703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526279703/ownership.xml","form_type":"4"}},{"id":728668,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-06-23T20:56:17.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"price":2.16,"value":500001.12,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On March 24, 2026, Factor Biosciences Inc. (\"Factor\") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. (\"Common Stock\") and warrants to purchase 462,964 shares of Common Stock (the \"Warrants\"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor."}],"balance_after":231482,"source":{"system":"sec-edgar","filing":"0001193125-26-279703","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526279703/ownership.xml","form_type":"4"}},{"id":828080,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-25T21:32:36.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"price":2.16,"value":500001.12,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Factor Bioscience Inc. (\"Factor\"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":231482,"source":{"system":"sec-edgar","filing":"0001931356-26-000011","document":"form4-03252026_090332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000193135626000011/form4-03252026_090332.xml","form_type":"4"}},{"id":915789,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-06T21:26:13.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":269621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":269621,"derivative":{"exercise_price":2.38,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":269621},"source":{"system":"sec-edgar","filing":"0001931356-26-000006","document":"form4-02062026_090210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000193135626000006/form4-02062026_090210.xml","form_type":"4"}},{"id":2055248,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-14T00:30:32.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":132003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vests and becomes exercisable over three years (subject to continued service), with 110,043 of the shares vesting on the grant date, and the remaining shares vesting in 36 substantially equal monthly tranches on the first day of each month thereafter."}],"balance_after":132003,"derivative":{"exercise_price":4.84,"expiration_date":"2033-01-12","underlying":"Common Stock, par value $0.005 per share","underlying_shares":132003},"source":{"system":"sec-edgar","filing":"0001140361-23-001698","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123001698/form4.xml","form_type":"4"}},{"id":2196773,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"officer_title":"Interim President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-04T00:01:34.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":2487003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable over four years (subject to continued service), with 2/48th of the shares vesting on the grant date and the remaining shares vesting in 46 substantially equal monthly installments thereafter."}],"balance_after":2487003,"derivative":{"exercise_price":0.49,"expiration_date":"2032-08-01","underlying":"Common Stock, par value $0.005 per share","underlying_shares":2487003},"source":{"system":"sec-edgar","filing":"0001140361-22-028096","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122028096/form4.xml","form_type":"4"}}]}